DiaMedica Therapeutics Inc (nasdaq:DMAC) Share Price

Company Profile

Business description
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Contact
301 Carlson Parkway
Suite 210
MinneapolisMN55305
USA
T: +1 763 496-5454
E: [email protected]
https://www.diamedica.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
28

Recommended

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Roy Van Keulen | 15 September 2025

Finding value in an expensive market.

Simonelle Mody | 15 September 2025

Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.

Joseph Taylor | 11 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,120.90	34.10	0.38%
CAC 40	7,901.63	76.39	0.98%
DAX 40	23,777.60	79.45	0.34%
Dow JONES (US)	45,834.22	273.78	-0.59%
FTSE 100	9,273.16	10.13	-0.11%
HKSE	26,446.56	58.40	0.22%
NASDAQ	22,141.10	98.03	0.44%
Nikkei 225	44,768.12	395.62	0.89%
NZX 50 Index	13,208.31	19.59	-0.15%
S&P 500	6,584.29	3.18	-0.05%
S&P/ASX 200	8,853.00	31.60	0.36%
SSE Composite Index	3,860.50	10.09	-0.26%